SCHEMBL104556

SCHEMBL104556

CC(C)c1ccc(NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
HPGD P15428 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
KIF11 P52732 1/20 0.51
CYP17A1 P05093 3/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
PSMB8 P28062 1/20 0.48
NAMPT P43490 1/20 0.48
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27284495 0.88 CYP17A1 (0.49) RAB9ANPC1HPGDSMN1; SMN2L3MBTL1
SCHEMBL27284560 0.88 CYP17A1 (0.49) RAB9ANPC1HPGDSMN1; SMN2L3MBTL1
SCHEMBL13055402 0.87 CYP17A1 (0.59) SMN1; SMN2L3MBTL1CYP17A1ALDH1A1PSMB8
SCHEMBL27872820 0.87 CYP17A1 (0.48) RAB9ANPC1HPGDSMN1; SMN2L3MBTL1
SCHEMBL12895659 0.87 CYP17A1 (0.48) RAB9ANPC1HPGDSMN1; SMN2L3MBTL1
SCHEMBL5106841 0.87 CYP17A1 (0.48) RAB9ANPC1HPGDSMN1; SMN2L3MBTL1
SCHEMBL24263030 0.86 CYP17A1 (0.50) RAB9ANPC1HPGDSMN1; SMN2L3MBTL1
SCHEMBL5726593 0.85 NR1H4 (0.57) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL5726217 0.85 NR1H4 (0.57) CYP17A1PSMB8NAMPTCA12CA1
SCHEMBL1000734 0.85 NR1H4 (0.57) CYP17A1PSMB8NAMPTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12458624-B2 Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides DHANOA DALJIT SINGH (US) 2025-11-04 US disclosed
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PROMEGA CORPORATION 2024-02-29 US disclosed
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
US-11781168-B2 Process for preparing substituted imidazo[1,2-α]pyrazines PROMEGA CORPORATION (US) 2023-10-10 US disclosed
US-11708346-B2 Treatment and prevention of neuropathic pain with P2Y14 antagonists SAINT LOUIS UNIVERSITY (US) 2023-07-25 US disclosed
CN-109563050-B Amide salt compound, catalyst for polyurethane production and method for producing polyurethane resin 广荣化学株式会社 2023-06-02 CN disclosed
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 US disclosed
CN-110475765-B Preparation method of amide compound 广荣化学株式会社 2023-04-07 CN disclosed
US-11584736-B2 Heterocyclic P2Y14 receptor antagonists THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-02-21 US disclosed
US-20230039319-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES DHANOA DALJIT SINGH (US) 2023-02-09 US disclosed
US-7893094-B2 Amphiphilic pyridinium compounds, method of making and use thereof THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2011-02-22 US disclosed
US-7807670-B2 Inhibitors of papilloma virus BOEHRINGER INGELHEIM CANADA LTD. (CA) 2010-10-05 US disclosed
US-20100041649-A1 INHIBITORS OF PAPILLOMA VIRUS YOAKIM CHRISTIANE 2010-02-18 US disclosed
US-7528167-B2 Inhibitors of papilloma virus BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2009-05-05 US disclosed
US-20080312319-A1 Modulation of Bacterial Quorum Sensing with Synthetic Ligands NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-18 US disclosed
US-20080312319-A1 Modulation of Bacterial Quorum Sensing with Synthetic Ligands NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-18 US disclosed
US-7312200-B2 9-ketospinosyn derivatives BAYER CROPSCIENCE AG (DE) 2007-12-25 US disclosed
US-7312200-B2 9-ketospinosyn derivatives BAYER CROPSCIENCE AG (DE) 2007-12-25 US disclosed
US-20070219176-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-09-20 US disclosed
US-20070105916-A1 Amphiphilic pyridinium compounds, method of making and use thereof THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039319-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES AGTR2, AGTR1, EDNRA RAB9A 3509/4885NPC1 4291/4885HPGD 593/4885
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators PDE4A, PDE4B, PDE5A RAB9A 604/4885NPC1 1428/4885HPGD 312/4885
US-11781168-B2 Process for preparing substituted imidazo[1,2-α]pyrazines CYP4Z1, CYP2E1, CYP2F1 RAB9A 2257/4885NPC1 3455/4885HPGD 590/4885
US-20070219176-A1 Viral Polymerase Inhibitors POLR2A, POLR2H, POLR2E RAB9A 1527/4885NPC1 1299/4885HPGD 1633/4885
US-11708346-B2 Treatment and prevention of neuropathic pain with P2Y14 antagonists P2RY14, P2RY4, P2RY13 RAB9A 3104/4885NPC1 2617/4885HPGD 440/4885
US-11584736-B2 Heterocyclic P2Y14 receptor antagonists P2RY14, P2RY1, P2RY13 RAB9A 809/4885NPC1 3086/4885HPGD 1131/4885
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 RAB9A 2771/4885NPC1 3034/4885HPGD 4086/4885
US-20080312319-A1 Modulation of Bacterial Quorum Sensing with Synthetic Ligands AHCYL1, EBPL, AIP RAB9A 4321/4885NPC1 4862/4885HPGD 1390/4885
US-20070105916-A1 Amphiphilic pyridinium compounds, method of making and use thereof CXCL8, IL18, CCR8 RAB9A 2796/4885NPC1 899/4885HPGD 396/4885
US-20100041649-A1 INHIBITORS OF PAPILLOMA VIRUS REV1, CDKN1A, RB1 RAB9A 2673/4885NPC1 1799/4885HPGD 1243/4885
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PGLS, AADAC, GLB1 RAB9A 2283/4885NPC1 3579/4885HPGD 1028/4885
US-12458624-B2 Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides AGTR2, AGTR1, EDNRA RAB9A 3509/4885NPC1 4291/4885HPGD 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.